The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Inhibits Proliferation and Induces Apoptosis of Burkitt Lymphoma Cells

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2015 Jul 2

PMID 26130968

Citations 10

Authors

Chuntuan Li

Pengliang Xin

Huifang Xiao

Yan Zheng

YuanLing Huang

Xiongpeng Zhu

Affiliations

Soon will be listed here.

Abstract

Background: Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a therapy target of cancer. We aimed to confirm the effect of dual PI3K/mTOR inhibitor NVP-BEZ235 on cell proliferation and apoptosis in Burkitt lymphoma (BL) cells.

Methods: Two human BL cell lines, CA46 and RAJI were used in this study. The proliferation of BL cells was detected by manganese tricarbonyl transfer (MTT) assay. Cell cycle and apoptosis assay were examined by flow cytometric analysis. The phosphorylation levels of AKT (Thr308), AKT (Ser473), and RPS6 were evaluated by western blot analysis.

Results: NVP-BEZ235 significantly inhibited the proliferation of BL cells (CA46 and RAJI) and the inhibition effect was time and dose-dependent. Cell cycle analysis indicated that the cells (CA46 and RAJI) were mostly arrested in G1/G0 phase. Cell apoptosis assay showed that the late apoptotic cells were significantly increased after 72 h treatment by 100 nmol/L of NVP-BEZ235. In addition, results also found that NVP-BEZ235 reduced the phosphorylation levels of AKT (Thr308), AKT (Ser473), and PRS6 in BL cells (CA46 and RAJI). Moreover, this inhibition effect on phosphorylation was dose-dependent.

Conclusions: NVP-BEZ235 effectively inhibited cell proliferation by G0/G1 cell-cycle arrest and induced apoptosis through deregulating PI3K/Akt/mTOR pathway in BL cells.

Citing Articles

Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma.

Kupcova K, Senavova J, Jura F, Herman V, Rajmonova A, Pacheco-Blanco M Exp Hematol Oncol. 2024; 13(1):108.

PMID: 39487517 PMC: 11529427. DOI: 10.1186/s40164-024-00568-6.

Discovery of first-in-class PROTACs targeting maternal embryonic leucine zipper kinase (MELK) for the treatment of Burkitt lymphoma.

Sun Y, Liu X, He Q, Zhang N, Yan W, Lv X RSC Med Chem. 2024; 15(7):2351-2356.

PMID: 39026635 PMC: 11253867. DOI: 10.1039/d4md00252k.

Role of PI3K/Akt pathway in Benzidine-induced proliferation in SV-40 immortalized human uroepithelial cell.

Ding D, Liu Z, Zhao L, Geng H, Liang Z, Yu D Transl Cancer Res. 2022; 8(4):1301-1310.

PMID: 35116872 PMC: 8798037. DOI: 10.21037/tcr.2019.07.14.

Role and mechanism of PTEN in Burkitt's lymphoma.

Li C, Xu Y, Xin P, Zheng Y, Zhu X Oncol Rep. 2020; 43(2):481-490.

PMID: 31922234 PMC: 6967105. DOI: 10.3892/or.2020.7457.

Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma.

Bhatti M, Ippolito T, Mavis C, Gu J, Cairo M, Lim M Oncotarget. 2018; 9(31):21820-21830.

PMID: 29774105 PMC: 5955151. DOI: 10.18632/oncotarget.25072.

References

Neise D, Sohn D, Stefanski A, Goto H, Inagaki M, Wesselborg S . The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma irradiation-induced apoptosis and mediates senescence via RSK- and p53-independent accumulation of p21WAF1/CIP1. Cell Death Dis. 2013; 4:e859. PMC: 3920941. DOI: 10.1038/cddis.2013.386. View

Aka P, Kawira E, Masalu N, Emmanuel B, Brubaker G, Magatti J . Incidence and trends in Burkitt lymphoma in northern Tanzania from 2000 to 2009. Pediatr Blood Cancer. 2012; 59(7):1234-8. PMC: 3427713. DOI: 10.1002/pbc.24194. View

Sander S, Rajewsky K . Burkitt lymphomagenesis linked to MYC plus PI3K in germinal center B cells. Oncotarget. 2012; 3(10):1066-7. PMC: 3717963. DOI: 10.18632/oncotarget.726. View

Mbulaiteye S, Anderson W, Ferlay J, Bhatia K, Chang C, Rosenberg P . Pediatric, elderly, and emerging adult-onset peaks in Burkitt's lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol. 2012; 87(6):573-8. PMC: 3358448. DOI: 10.1002/ajh.23187. View

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

Cerniglia G, Karar J, Tyagi S, Christofidou-Solomidou M, Rengan R, Koumenis C . Inhibition of autophagy as a strategy to augment radiosensitization by the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Mol Pharmacol. 2012; 82(6):1230-40. PMC: 3502620. DOI: 10.1124/mol.112.080408. View

Pajic A, Spitkovsky D, Christoph B, Kempkes B, Schuhmacher M, Staege M . Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000; 87(6):787-93. DOI: 10.1002/1097-0215(20000915)87:6<787::aid-ijc4>3.0.co;2-6. View

Sekiguchi N, Nishimoto J, Tanosaki R, Kubota N, Yokota Y, Kobayashi Y . EBV-positive Burkitt lymphoma as a late-onset posttransplantion lymphoproliferative disorder after allogeneic stem cell transplantation. Int J Hematol. 2004; 79(4):387-9. DOI: 10.1532/ijh97.03175. View

Bouchard C, Marquardt J, Bras A, Medema R, Eilers M . Myc-induced proliferation and transformation require Akt-mediated phosphorylation of FoxO proteins. EMBO J. 2004; 23(14):2830-40. PMC: 514943. DOI: 10.1038/sj.emboj.7600279. View

10.

Cairo M, Gerrard M, Sposto R, Auperin A, Pinkerton C, Michon J . Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2006; 109(7):2736-43. PMC: 1852225. DOI: 10.1182/blood-2006-07-036665. View

11.

Morgensztern D, McLeod H . PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs. 2005; 16(8):797-803. DOI: 10.1097/01.cad.0000173476.67239.3b. View

12.

Mbulaiteye S, Clarke C, Morton L, Gibson T, Pawlish K, Weisenburger D . Burkitt lymphoma risk in U.S. solid organ transplant recipients. Am J Hematol. 2013; 88(4):245-50. PMC: 3608801. DOI: 10.1002/ajh.23385. View

13.

Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Redini F . NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett. 2013; 344(2):291-8. DOI: 10.1016/j.canlet.2013.11.017. View

14.

Mukherjee B, Tomimatsu N, Amancherla K, Camacho C, Pichamoorthy N, Burma S . The dual PI3K/mTOR inhibitor NVP-BEZ235 is a potent inhibitor of ATM- and DNA-PKCs-mediated DNA damage responses. Neoplasia. 2012; 14(1):34-43. PMC: 3281940. DOI: 10.1593/neo.111512. View

15.

Wan X, Helman L . Effect of insulin-like growth factor II on protecting myoblast cells against cisplatin-induced apoptosis through p70 S6 kinase pathway. Neoplasia. 2002; 4(5):400-8. PMC: 1564119. DOI: 10.1038/sj.neo.7900242. View

16.

Maira S, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C . Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7(7):1851-63. DOI: 10.1158/1535-7163.MCT-08-0017. View

17.

Molyneux E, Rochford R, Griffin B, Newton R, Jackson G, Menon G . Burkitt's lymphoma. Lancet. 2012; 379(9822):1234-44. DOI: 10.1016/S0140-6736(11)61177-X. View

18.

Mutalima N, Molyneux E, Jaffe H, Kamiza S, Borgstein E, Mkandawire N . Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One. 2008; 3(6):e2505. PMC: 2423475. DOI: 10.1371/journal.pone.0002505. View

19.

Perkins A, Friedberg J . Burkitt lymphoma in adults. Hematology Am Soc Hematol Educ Program. 2008; :341-8. DOI: 10.1182/asheducation-2008.1.341. View

20.

Padmanabhan J, Brown K, Padilla A, Shelanski M . Functional role of RNA polymerase II and P70 S6 kinase in KCl withdrawal-induced cerebellar granule neuron apoptosis. J Biol Chem. 2015; 290(9):5267-79. PMC: 4342447. DOI: 10.1074/jbc.M114.575225. View